Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties

Chinese Medical Journal

Volumn 126, Issue 16, 2013, Pages 3030-3034

  Liu, Hui ^a   Zhang, Heng Wei ^a   Sun, Xian Fu ^a   Guo, Xu Hui ^a   He, Ya Ning ^a   Cui, Shu De ^a   Fan, Qing Xia ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer stem cells; Epithelial mesenchymal transition; Tamoxifen resistance

Indexed keywords

CD133 ANTIGEN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; TAMOXIFEN; TRANSCRIPTION FACTOR SOX; UVOMORULIN; VIMENTIN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CELL ADHESION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MCF-7 CELLS; MICE; NEOPLASTIC STEM CELLS; TAMOXIFEN;

EID: 84882265082     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130227     Document Type: Article

References (32)

1. Beatson GT. On the treatment of inoperable cases of carcinogen of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107, 162-167.
2. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006; 13: 15-24.
3. Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003; 10: 112-119.
4. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9: 447-454.
5. Zilli M, Grassadonia A, Tinari N, Di Giacobbe A, Gildetti S, Giampietro J, et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta 2009; 1795: 62-81.
6. Johnston SR. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 1997; 8: 911-930.
7. Normanno N, Di Maio M, De Maio E, De Luca A, De Matteis A, Giordano A, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12: 721-747.
8. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005; 591: 247-263.
9. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16: 3113-3120.
10. Lin ZX. Patterns in the occurrence and development of tumors. Chin Med J 2011; 124: 1097-1104.
11. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
12. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120.
13. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66: 1883-1890.
14. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF7 cells. Endocrinology 2003; 144: 1032.
15. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by geftinib ('Iressa', ZD1839). Clin Exp Metastasis 2004; 21: 201-212.
16. Yang JP, Liu Y, Zhong W, Yu D, Wen LJ, Jin CS. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Chin Med J 2011; 124: 1055-1060.
17. Kim K, Ihm H, Ro JY, Cho YM. High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncol Lett 2011; 2: 1095-1100.
18. Kemmerling R, Alinger B, Dietze O, Bösmüller HC, Ocker M, Wolkersdörfer GW, et al. Association of stem cell marker expression pattern and survival in human biliary tract cancer. Int J Oncol 2012; 41: 511-522.
19. Zhou C, Liu J, Tang Y, Liang X. Infammation linking EMT and cancer stem cells. Oral Oncol 2012; 48: 1068-1075.
20. Cioce M, Ciliberto G. On the connections between cancer stem cells and EMT. Cell Cycle 2012; 11: 4301.
21. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 2012; 31: 285-293.
22. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Invovement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 2009; 100: 1834-1841.
23. Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010; 5: e13831.
24. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994; 32: 49-55.
25. Lawson JC, Blatch GL, Edkins AL. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat 2009; 118: 241-254.
26. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-1479.
27. Kai K, Arima Y, Kamiya T, Saya H. Breast cancer stem cells. Breast Cancer 2010; 17: 80-85.
28. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
29. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3: e2888.
30. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
31. Xu XF, Dai HP. Type 2 epithelial mesenchymal transition in vivo: truth or pitfalls? Chin Med J 2012; 125: 3312-3317.
32. Han L, Zhang HW, Zhou WP, Chen GM, Guo KJ. The effects of genistein on transforming growth factor-β1-induced invasion and metastasis in human pancreatic cancer cell line Panc-1 in vitro. Chin Med J 2012; 125: 2032-2040.